VILOXAZINE

Course overview

VILOXAZINE WAS MARKETED AS AN ANTIDEPRESSANT IN EUROPE FOR MORE THAN 2 DECADES UNDER AN IMMEDIATE-RELEASE FORMULATION BEFORE ITS POTENTIAL AS A TREATMENT FOR PATIENTS WITH ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) WAS CONSIDERED. VILOXAZINE RECEIVED ITS FIRST ENDORSEMENT IN THE UNITED KINGDOM IN 1971 AND WAS SUBSEQUENTLY RECOGNIZED AS AN ANTIDEPRESSANT IN SEVERAL OTHER NATIONS. HOWEVER, COMMERCIAL REASONS LED TO ITS DISCONTINUATION IN 2002. IN APRIL 2021, THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVED VILOXAZINE EXTENDED-RELEASE CAPSULES FOR CHILDREN AND ADOLESCENTS WITH ADHD. RESEARCH SUGGESTS THAT THE MECHANISM OF ACTION OF VILOXAZINE IS CLOSELY LINKED TO INHIBITING THE REUPTAKE OF NOREPINEPHRINE. NOTABLY, THE (S) STEREOISOMER OF VILOXAZINE EXHIBITS 10 TIMES GREATER POTENCY THAN THE (R) STEREOISOMER. THIS ACTIVITY PROVIDES A COMPREHENSIVE SUMMARY OF THE ESSENTIAL ASPECTS OF VILOXAZINE THERAPY IN THE CLINICAL SETTING, INCLUDING INDICATIONS, ADMINISTRATION, DOSES, CONTRAINDICATIONS, MECHANISM OF ACTION, ADVERSE EVENTS, AND OTHER CRUCIAL INFORMATION RELEVANT TO THE INTERPROFESSIONAL TEAM RESPONSIBLE FOR MANAGING AND TREATING ADHD IN PATIENTS.